NSIM
BCRX icon

North Star Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

North Star Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-200
Closed -$1.24K – 1190
2024
Q2 		$1.24K Hold
200
– – ﹤0.01% 1081
2024
Q1 		$1.02K Buy
+200
New +$1.13K ﹤0.01% 1156
2023
Q2 		– Sell
-20,000
Closed -$167K – 1295
2023
Q1 		$167K Sell
20,000
-347,300
-95% -$3.34M 0.01% 450
2022
Q4 		$4.22M Sell
367,300
-74,600
-17% -$930K 0.37% 66
2022
Q3 		$5.57M Hold
441,900
– – 0.55% 42
2022
Q2 		$4.67M Sell
441,900
-1,500
-0.3% -$15.5K 0.43% 59
2022
Q1 		$7.21M Sell
443,400
-6,400
-1% -$103K 0.56% 38
2021
Q4 		$6.23M Buy
449,800
+6,900
+2% +$91.3K 0.44% 53
2021
Q3 		$6.36M Buy
442,900
+6,210
+1% +$97.9K 0.52% 48
2021
Q2 		$6.9M Buy
436,690
+900
+0.2% +$12.2K 0.55% 44
2021
Q1 		$4.43M Buy
435,790
+135,600
+45% +$1.4M 0.42% 65
2020
Q4 		$2.24M Buy
300,190
+125,190
+72% +$645K 0.23% 109
2020
Q3 		$601K Buy
175,000
+135,000
+338% +$579K 0.07% 224
2020
Q2 		$191K Buy
+40,000
New +$160K 0.02% 332

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

North Star Investment Management's BCRX Position: Q3 2024 in Review

North Star Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 200 shares — an estimated $1.24K sold.

North Star Investment Management first reported a position in BCRX in Q2 2020 and held it in 14 quarters. The position peaked at $7.21M in Q1 2022. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

  • North Star Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • North Star Investment Management sold 200 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $1.24K.
  • North Star Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • North Star Investment Management's BioCryst Pharmaceuticals position peaked at $7.21M in Q1 2022.
  • 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on North Star Investment Management's 13F filing for Q3 2024, filed 30 Oct 2024.